# TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT04891900** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Gastric Cancer
- Adenocarcinoma of Esophagogastric Junction

## Interventions

- **DRUG:** TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine

## Key facts

- **NCT ID:** NCT04891900
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891900, "TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04891900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*